```
FILE 'HOME' ENTERED AT 21:35:59 ON 11 MAY 2003

=> FIL BIOSIS,CABA,CAPLUS,EMBASE,LIFESCI,MEDLINE,SCISEARCH,USPATFULL,JAPIO
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'BIOSIS' ENTERED AT 21:36:06 ON 11 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CABA' ENTERED AT 21:36:06 ON 11 MAY 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 21:36:06 ON 11 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 21:36:06 ON 11 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'LIFESCI' ENTERED AT 21:36:06 ON 11 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'MEDLINE' ENTERED AT 21:36:06 ON 11 MAY 2003

FILE 'SCISEARCH' ENTERED AT 21:36:06 ON 11 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'USPATFULL' ENTERED AT 21:36:06 ON 11 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 21:36:06 ON 11 MAY 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

=> e bar-or
E1            1     BAQY/BI
E2       605583     BAR/BI
E3            0 --> BAR-OR/BI
E4          927     BAR0/BI
E5            1     BAR0.741/BI
E6            1     BAR0.97VERTICAL/BI
E7           11     BAR00/BI
E8            5     BAR01/BI
E9            1     BAR011VERTICAL/BI
E10           6     BAR012/BI
E11           4     BAR012010/BI
E12           1     BAR0174/BI

=> e bar
E1            3     BAQWA/BI
E2            1     BAQY/BI
E3       605583 --> BAR/BI
E4          927     BAR0/BI
E5            1     BAR0.741/BI
E6            1     BAR0.97VERTICAL/BI
E7           11     BAR00/BI
E8            5     BAR01/BI
E9            1     BAR011VERTICAL/BI
E10           6     BAR012/BI
E11           4     BAR012010/BI
E12           1     BAR0174/BI

=> s e3 and david
```

```
L1      3363 BAR/BI AND DAVID

=> s l1 and ischemia
L2         126 L1 AND ISCHEMIA

=> s l2 and lau
L3           4 L2 AND LAU

=> d l3 1-4 ibib abs

L3   ANSWER 1 OF 4  USPATFULL
ACCESSION NUMBER:        2003:120747  USPATFULL
TITLE:                   Blood cell deficiency treatment method
INVENTOR(S):             Ahlem, Clarence N., San Diego, CA, UNITED STATES
                         Reading, Christopher, San Diego, CA, UNITED STATES
                         Frincke, James, San Diego, CA, UNITED STATES
                         Stickney, Dwight, Granite Bay, CA, UNITED STATES
                         Lardy, Henry A., Madison, WI, UNITED STATES
                         Marwah, Padma, Middleton, WI, UNITED STATES
                         Marwah, Ashok, Middleton, WI, UNITED STATES
                         Prendergast, Patrick T., Straffan, IRELAND

                              NUMBER         KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003083231      A1   20030501
APPLICATION INFO.:       US 2002-87929      A1   20020301  (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2000-675470, filed
                         on 28 Sep 2000, PENDING Continuation-in-part of Ser.
                         No. US 2001-820483, filed on 29 Mar 2001, PENDING
                         Continuation-in-part of Ser. No. US 2000-535675, filed
                         on 23 Mar 2000, PENDING Continuation-in-part of Ser.
                         No. US 1999-449004, filed on 24 Nov 1999, ABANDONED
                         Continuation-in-part of Ser. No. US 1999-449184, filed
                         on 24 Nov 1999, ABANDONED Continuation-in-part of Ser.
                         No. US 1999-449042, filed on 24 Nov 1999, ABANDONED
                         Continuation-in-part of Ser. No. US 1999-461026, filed
                         on 15 Dec 1999, ABANDONED Continuation-in-part of Ser.
                         No. US 2000-586673, filed on 1 Jun 2000, ABANDONED
                         Continuation-in-part of Ser. No. US 2000-586672, filed
                         on 1 Jun 2000, ABANDONED Continuation-in-part of Ser.
                         No. US 1999-414905, filed on 8 Oct 1999, ABANDONED

                              NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 1999-161453P    19991025 (60)
                         US 2001-272624P    20010301 (60)
                         US 2001-323016P    20010911 (60)
                         US 2001-340045P    20011130 (60)
                         US 2001-328738P    20011011 (60)
                         US 2001-338015P    20011108 (60)
                         US 2001-343523P    20011220 (60)
                         US 1999-126056P    19991019 (60)
                         US 1999-124087P    19990311 (60)
                         US 1998-109923P    19981124 (60)
                         US 1998-109924P    19981124 (60)
                         US 1998-110127P    19981127 (60)
                         US 1998-112206P    19981215 (60)
                         US 1999-145823P    19990727 (60)
                         US 1999-137745P    19990603 (60)
                         US 1999-140028P    19990616 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,
                         SUITE 400, SAN DIEGO, CA, 92121
NUMBER OF CLAIMS:        45
```

EXEMPLARY CLAIM: 1
LINE COUNT: 19428
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

L3 ANSWER 2 OF 4 USPATFULL
ACCESSION NUMBER: 2003:100088 USPATFULL
TITLE: Treatment methods based on microcompetition for a limiting GABP complex
INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069199	A1	20030410
APPLICATION INFO.:	US 2002-219334	A1	20020815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Hanan Polansky, 3159 S. Winton Rd., Rochester, NY, 14623
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 14837
AB Microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor associated with chronic disease such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present methods for the treatment of these chronic diseases. The methods are based on modifying such microcompetition, or the effect of such microcompetition on the cell. For instance, treatment may modify the cellular copy number of the foreign polynucleotide, change the rate of complex formation between GABP and either the foreign polynucleotide or the cellular GABP regulated gene, vary the expression of the cellular GABP regulated gene, or manipulate the activity of the gene product of the cellular GABP regulated gene. The invention also presents methods for treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

L3 ANSWER 3 OF 4 USPATFULL
ACCESSION NUMBER: 2003:99511 USPATFULL
TITLE: Drug discovery assays based on microcompetition for a limiting GABP complex
INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003068616	A1	20030410
APPLICATION INFO.:	US 2002-223050	A1	20020814 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Hanan Polansky, 3159 S. Winton Rd., Rochester, NY,

14623
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 14981
AB A recent discovery showed that microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor for some of the major chronic diseases, such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present assays for screening compounds based on their effectiveness in modulating such microcompetition, or the effects of such microcompetition on the cell. The selected compounds can be used in treatment of these chronic diseases. The invention also presents assays for screening compounds that can be used in treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

L3 ANSWER 4 OF 4 USPATFULL
ACCESSION NUMBER: 2002:81054 USPATFULL
TITLE: Senscent cell-derived inhibitors of DNA synthesis
INVENTOR(S): Smith, James R., Houston, TX, United States
Drutz, David J., Houston, TX, United States
Wilson, Deborah R., Houston, TX, United States
Zumstein, Louis A., Houston, TX, United States
PATENT ASSIGNEE(S): Baylor College of Medicine, Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6372249	B1	20020416
APPLICATION INFO.:	US 1994-327874		19941024 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1994-US9700, filed on 26 Aug 1994 Continuation-in-part of Ser. No. US 1994-274535, filed on 13 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-229420, filed on 15 Apr 1994, now abandoned Continuation-in-part of Ser. No. US 1994-203535, filed on 25 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-153564, filed on 17 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1993-113372, filed on 30 Aug 1993, now abandoned Continuation-in-part of Ser. No. US 1992-970462, filed on 2 Nov 1992, now patented, Pat. No. US 5302706, issued on 12 Apr 1994 Continuation-in-part of Ser. No. US 327874 Division of Ser. No. US 1994-268439, filed on 30 Jun 1994, now abandoned Division of Ser. No. US 1994-160814, filed on 3 Jan 1994, now patented, Pat. No. US 5424400 Continuation-in-part of Ser. No. US 1991-808523, filed on 16 Dec 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Norton, Esq., Gerard P., Clifford Chance Rogers & Wells LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 5347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening

. untranslated regions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l1 and ischemia
L4 126 L1 AND ISCHEMIA

=> s l4 and cobalt
L5 9 L4 AND COBALT

=> d l5 1-9 ibib abs

L5 ANSWER 1 OF 9 USPATFULL
ACCESSION NUMBER: 2003:51209 USPATFULL
TITLE: ErbB4 receptor-specific neuregulin related ligands and uses therefor
INVENTOR(S): Godowski, Paul J., Burlingame, CA, UNITED STATES
Mark, Melanie Rose, Burlingame, CA, UNITED STATES
Zhang, Dong Xiao, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003036166	A1	20030220
APPLICATION INFO.:	US 2002-215862	A1	20020809 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-126663, filed on 30 Jul 1998, ABANDONED Division of Ser. No. US 1997-899437, filed on 24 Jul 1997, GRANTED, Pat. No. US 6121415

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52019P	19970709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 9 USPATFULL
ACCESSION NUMBER: 2002:332754 USPATFULL
TITLE: Method for treating multiple sclerosis
INVENTOR(S): Hunter, William L., Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6495579 B1 20021217
APPLICATION INFO.: US 1998-88546 19980601 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63087P	19971024 (60)
	US 1996-32215P	19961202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Geist, Gary
ASSISTANT EXAMINER: Crane, L. E.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 167 Drawing Figure(s); 107 Drawing Page(s)
LINE COUNT: 8213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 9 USPATFULL
ACCESSION NUMBER: 2002:323211 USPATFULL
TITLE: Compositions and methods for treating or preventing inflammatory diseases
INVENTOR(S): Hunter, William L., Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183380	A1	20021205
APPLICATION INFO.:	US 2002-67467	A1	20020205 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-368463, filed on 4 Aug 1999, ABANDONED Division of Ser. No. US 1998-88546, filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32215P	19961202 (60)
	US 1997-63087P	19971024 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 107 Drawing Page(s)
LINE COUNT: 8178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 9 USPATFULL
ACCESSION NUMBER: 2002:294637 USPATFULL

TITLE: ErbB4 receptor-specific neuregulin related ligands and uses therefor
INVENTOR(S): Godowski, Paul J., Burlingame, CA, UNITED STATES
Mark, Melanie Rose, Burlingame, CA, UNITED STATES
Zhang, Dong-Xiao, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164680	A1	20021107
APPLICATION INFO.:	US 2001-877665	A1	20010608 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-109206, filed on 30 Jun 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52019P	19970709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 9 USPATFULL
ACCESSION NUMBER: 2002:288328 USPATFULL
TITLE: ErbB4 receptor-specific neuregulin related ligands and uses therefor
INVENTOR(S): Godowski, Paul J., Burlingame, CA, UNITED STATES
Mark, Melanie Rose, Burlingame, CA, UNITED STATES
Zhang, Dong Xiao, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (2)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002161200	A1	20021031
APPLICATION INFO.:	US 2002-136573	A1	20020429 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-480977, filed on 11 Jan 2000, PENDING Continuation of Ser. No. US 1997-899437, filed on 24 Jul 1997, GRANTED, Pat. No. US 6121415

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52019P	19970709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 38

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 4345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 9 USPATFULL
ACCESSION NUMBER: 2002:157624 USPATFULL
TITLE: ErbB4 receptor-specific neuregulin related ligands and uses therefor
INVENTOR(S): Godowski, Paul J., Burlingame, CA, UNITED STATES
Mark, Melanie Rose, Burlingame, CA, UNITED STATES
Zhang, Dong-Xiao, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002082229	A1	20020627
APPLICATION INFO.:	US 2001-817647	A1	20010326 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-107979, filed on 30 Jun 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-53641P	19970724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain; a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 9 USPATFULL
ACCESSION NUMBER: 2002:22462 USPATFULL
TITLE: COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES
INVENTOR(S): HUNTER, WILLIAM L., VANCOUVER, CANADA

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2002013298	A1	20020131
APPLICATION INFO.:	US 1999-368463	A1	19990804 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-88546, filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32215P	19961202 (60)
	US 1997-63087P	19971024 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 110 Drawing Page(s)
LINE COUNT: 8318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 9 USPATFULL
ACCESSION NUMBER: 2001:98071 USPATFULL
TITLE: ErbB4 receptor-specific neuregulin related ligand antibodies and uses therefor
INVENTOR(S): Godowski, Paul J., Burlingame, CA, United States
Mark, Melanie Rose, Burlingame, CA, United States
Zhang, Dong Xiao, Burlingame, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6252051	B1	20010626
APPLICATION INFO.:	US 1998-126121		19980730 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-899437, filed on 24 Jul 1997, now patented, Pat. No. US 6121415, issued on 19 Sep 2000

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52019P	19970709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Nickol, Gary
LEGAL REPRESENTATIVE: Conley, Deirdre L.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression

vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 9 USPATFULL

ACCESSION NUMBER:	2000:125191 USPATFULL
TITLE:	ErbB4 receptor-specific neuregolin related ligands and uses therefor
INVENTOR(S):	Godowski, Paul J., Burlingame, CA, United States Mark, Melanie Rose, Burlingame, CA, United States Zhang, Dong Xiao, Burlingame, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121415		20000919
APPLICATION INFO.:	US 1997-899437		19970724 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52019P	19970709 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Eyler, Yvonne
LEGAL REPRESENTATIVE:	Conley, Deidre L.
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:	4325

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l4 and cobalt
L6 9 L4 AND COBALT

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 21:35:59 ON 11 MAY 2003)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 21:36:06 ON 11 MAY 2003

E BAR-OR
E BAR
L1 3363 S E3 AND DAVID

```
L2          126 S L1 AND ISCHEMIA
L3            4 S L2 AND LAU
L4          126 S L1 AND ISCHEMIA
L5            9 S L4 AND COBALT
L6            9 S L4 AND COBALT

=> s l2 and cobalt
L7            9 L2 AND COBALT

=> s l2 and albumin
L8           87 L2 AND ALBUMIN

=> s l8 and ions
L9           24 L8 AND IONS

=>  rem dup l9
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the
system.

To delete a saved query, saved answer set, saved L-number list, SDI
request, batch request, mailing list, or user-defined cluster, format,
or search field, enter the name.  The name may include ?  for left,
right, or simultaneous left and right truncation.

Examples:

  DELETE BIO?/Q           - delete query names starting with BIO
  DELETE ?DRUG/A          - delete answer set names ending with DRUG
  DELETE ?ELEC?/L         - delete L-number lists containing ELEC
  DELETE ANTICOAG/S       - delete SDI request
  DELETE ENZYME/B         - delete batch request
  DELETE .MYCLUSTER       - delete user-defined cluster
  DELETE .MYFORMAT        - delete user-defined display format
  DELETE .MYFIELD         - delete user-defined search field
  DELETE NAMELIST MYLIST - delete mailing list

To delete an ordered document or an offline print, enter its
number.

Examples:

  DELETE P123001C         - delete print request
  DELETE D134002C         - delete document order request

To delete an individual L-number or range of L-numbers, enter the
L-number or L-number range.  You may also enter DELETE LAST followed
by a number, n, to delete the last n L-numbers.  RENUMBER or
NORENUMBER may also be explicitly specified to override the value of
SET RENUMBER.

Examples:

  DELETE L21              - delete a single L-number
  DELETE L3-L6            - delete a range of L-numbers
  DELETE LAST 4           - delete the last 4 L-numbers
  DELETE L33-             - delete L33 and any higher L-number
  DELETE -L55             - delete L55 and any lower L-number
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER         - renumber L-numbers after deletion of
                          intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined
items, or E-numbers can be deleted.
```

Examples:

```
  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1
```

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

```
=> dup rem l9
PROCESSING COMPLETED FOR L9
L10          24 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l10 and cardiac
L11          11 L10 AND CARDIAC

=> d l11 1-11 ibib abs

L11  ANSWER 1 OF 11  USPATFULL
ACCESSION NUMBER:        2003:127127  USPATFULL
TITLE:                   Novel human leucine-rich repeat containing protein
                         expressed predominately in nervous system tissues,
                         HLRRNS1
INVENTOR(S):             Feder, John N., Belle Mead, NJ, UNITED STATES
                         Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
                         Mintier, Gabe, Hightstown, NJ, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003087340      A1   20030508
APPLICATION INFO.:       US 2001-28392      A1   20011220  (10)

                                NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2001-259479P    20010103 (60)
                         US 2001-260616P    20010109 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT
                         DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS:        23
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      12 Drawing Page(s)
LINE COUNT:              15374
AB       The present invention provides novel polynucleotides encoding HLRRNS1
         polypeptides, fragments and homologues thereof. Also provided are
         vectors, host cells, antibodies, and recombinant and synthetic methods
         for producing said polypeptides. The invention further relates to
         diagnostic and therapeutic methods for applying these novel HLRRNS1
         polypeptides to the diagnosis, treatment, and/or prevention of various
         diseases and/or disorders related to these polypeptides, particularly
         nervous system diseases and/or disorders. The invention further relates
         to screening methods for identifying agonists and antagonists of the
```

polynucleotides and polypeptides of the present invention.

L11 ANSWER 2 OF 11 USPATFULL

ACCESSION NUMBER: 2003:120747 USPATFULL

TITLE: Blood cell deficiency treatment method

INVENTOR(S): Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083231	A1	20030501
APPLICATION INFO.:	US 2002-87929	A1	20020301 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-161453P	19991025 (60)
	US 2001-272624P	20010301 (60)
	US 2001-323016P	20010911 (60)
	US 2001-340045P	20011130 (60)
	US 2001-328738P	20011011 (60)
	US 2001-338015P	20011108 (60)
	US 2001-343523P	20011220 (60)
	US 1999-126056P	19991019 (60)
	US 1999-124087P	19990311 (60)
	US 1998-109923P	19981124 (60)
	US 1998-109924P	19981124 (60)
	US 1998-110127P	19981127 (60)
	US 1998-112206P	19981215 (60)
	US 1999-145823P	19990727 (60)
	US 1999-137745P	19990603 (60)
	US 1999-140028P	19990616 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121

NUMBER OF CLAIMS: 45

EXEMPLARY CLAIM: 1

LINE COUNT: 19428

AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-

androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

L11 ANSWER 3 OF 11 USPATFULL

ACCESSION NUMBER: 2003:86817 USPATFULL

TITLE: Immune modulation method using steroid compounds

INVENTOR(S): Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060425	A1	20030327
APPLICATION INFO.:	US 2001-820483	A1	20010329 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-109924P	19981124 (60)
	US 1999-140028P	19990616 (60)
	US 1998-109923P	19981124 (60)
	US 1999-126056P	19991019 (60)
	US 1999-124087P	19990311 (60)
	US 1998-110127P	19981127 (60)
	US 1999-161453P	19991025 (60)
	US 1999-145823P	19990727 (60)
	US 1999-137745P	19990603 (60)
	US 1998-112206P	19981215 (60)
	US 2000-257071P	20001220 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121

NUMBER OF CLAIMS: 54

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 14708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions comprising formula 1 steroids, e.g., 16.alpha.-bromo-3 .beta.-hydroxy-5.alpha.-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The

compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 11 USPATFULL

ACCESSION NUMBER: 2003:78522 USPATFULL

TITLE: IL-17 homologous polypeptides and therapeutic uses thereof

INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Fong, Sherman, Alameda, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., HIllsborough, CA, UNITED STATES
Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES
Gurney, Austin, Belmont, CA, UNITED STATES
Li, Hanzhong, San Mateo, CA, UNITED STATES
Hillan, Kenneth, San Francisco, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
VanLookeren, Menno, San Francisco, CA, UNITED STATES
Vandlen, Richard, Hillsborough, CA, UNITED STATES
Watanabe, Colin K., Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Yansura, Daniel, Pacifica, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003054442	A1	20030320
APPLICATION INFO.:	US 2001-908827	A1	20010718 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-311832, filed on 14 May 1999, PENDING Continuation of Ser. No. US 1999-380138, filed on 25 Aug 1999, PENDING Continuation of Ser. No. US 1999-380142, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US 2000-644848, filed on 22 Aug 2000, PENDING Continuation of Ser. No. US 2000-747259, filed on 20 Dec 2000, PENDING Continuation of Ser. No. US 2001-816744, filed on 22 Mar 2001, PENDING Continuation of Ser. No. US 2001-854208, filed on 10 May 2001, PENDING Continuation of Ser. No. US 2001-854280, filed on 10 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1999-US5028	19990308
	WO 1999-US10733	19990514
	WO 1999-US31274	19991230
	WO 2000-US4341	20000218
	WO 2000-US5601	20000301
	WO 2000-US5841	20000302
	WO 2000-US7532	20000321
	WO 2000-US15264	20000602
	WO 2000-US23328	20000824
	WO 2000-US30873	20001110
	WO 2000-US32678	20001201

	WO 2000-US34956	20001220
	WO 2001-US6520	20010228
	US 1998-85579P	19980515 (60)
	US 1998-113621P	19981223 (60)
	US 1999-130232P	19990421 (60)
	US 1999-131022P	19990426 (60)
	US 1999-134287P	19990514 (60)
	US 1999-138387P	19990609 (60)
	US 1999-172096P	19991223 (60)
	US 2000-175481P	20000111 (60)
	US 2000-191007P	20000321 (60)
	US 2000-213807P	20000622 (60)
	US 2000-242837P	20001024 (60)
	US 2000-244072P	20001026 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 47 Drawing Page(s)
LINE COUNT: 8091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 11 USPATFULL
ACCESSION NUMBER: 2003:23722 USPATFULL
TITLE: Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003017562	A1	20030123
APPLICATION INFO.:	US 2001-29347	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257774P	20001222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 14217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly

gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 11 USPATFULL

ACCESSION NUMBER: 2003:11111 USPATFULL

TITLE: IL-17 homologous polypeptides and therapeutic uses thereof

INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Fong, Sherman, Alameda, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., Burlingame, CA, UNITED STATES
Grimaldi, Christopher, San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Li, Hanzhong, San Mateo, CA, UNITED STATES
Hillan, Kenneth, San Francisco, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
VanLookeren, Menno, San Francisco, CA, UNITED STATES
Vandlen, Richard, Hillsborough, CA, UNITED STATES
Watanabe, Colin, Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Yansura, Daniel G., Pacifica, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008815	A1	20030109
APPLICATION INFO.:	US 2000-747259	A1	20001220 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-311832, filed on 14 May 1999, PENDING Continuation-in-part of Ser. No. US 2000-644848, filed on 22 Aug 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US4341, filed on 18 Feb 2000, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US23328, filed on 24 Aug 2000, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US32678, filed on 1 Dec 2000, UNKNOWN Continuation-in-part of Ser. No. WO 1999-US31274, filed on 30 Dec 1999, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US7532, filed on 21 Mar 2000, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US5841, filed on 2 Mar 2000, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US15264, filed on 2 Jun 2000, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US30873, filed on 10 Nov 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253646P	20001128 (60)
	US 1999-172096P	19991223 (60)
	US 2000-175481P	20000111 (60)
	US 2000-191007P	20000321 (60)
	US 2000-213087P	20000620 (60)
	US 2000-242837P	20001024 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

NUMBER OF CLAIMS: 60

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 47 Drawing Page(s)

LINE COUNT: 8685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 11 USPATFULL

ACCESSION NUMBER: 2003:3511 USPATFULL

TITLE: 1L-17 homologous polypeptides and therapeutic uses thereof

INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Fong, Sherman, Alameda, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul, Burlingame, CA, UNITED STATES
Grimaldi, Christopher, San Francisco, CA, UNITED STATES
Gurney, Austin, Belmont, CA, UNITED STATES
Li, Hanzhong, San Mateo, CA, UNITED STATES
Hillan, Kenneth, San Francisco, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
VanLookeren, Menno, San Francisco, CA, UNITED STATES
Vandlen, Richard, Hillsborough, CA, UNITED STATES
Watanabe, Colin, Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Yansura, Daniel, Pacifica, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003003546	A1	20030102
APPLICATION INFO.:	US 2001-816744	A1	20010322 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-311832, filed on 14 May 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US6520	20010228
	WO 2000-US34956	20001220
	WO 2000-US32678	20001201
	WO 2000-US30873	20001110
	WO 2000-US23328	20000824
	WO 2000-US15264	20000602
	WO 2000-US7532	20000321
	WO 2000-US5841	20000302
	WO 2000-US5601	20000301
	WO 2000-US4341	20000218
	WO 1999-US31274	19991230
	WO 1999-US10733	19990514
	WO 1999-US5028	19990308
	US 2000-253646P	20001128 (60)
	US 2000-244072P	20001026 (60)
	US 2000-242837P	20001024 (60)
	US 2000-213807P	20000622 (60)
	US 2000-191007P	20000321 (60)
	US 2000-175481P	20000111 (60)
	US 1999-172096P	19991223 (60)
	US 1999-138387P	19990609 (60)
	US 1999-134287P	19990514 (60)
	US 1999-131022P	19990426 (60)
	US 1999-130232P	19990421 (60)

US 1998-113621P 19981223 (60)
US 1998-85579P 19980515 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Page(s)
LINE COUNT: 7774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 11 USPATFULL
ACCESSION NUMBER: 2002:322509 USPATFULL
TITLE: IL-17 homologous polypedies and therapeutic uses thereof
INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Fong, Sherman, Alameda, CA, UNITED STATES
French, Dorothy, Redwood City, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., Hillsborough, CA, UNITED STATES
Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
Hymowitz, Sarah G., San Francisco, CA, UNITED STATES
Li, Hanzhong, San Mateo, CA, UNITED STATES
Pan, James, Zitobicoke, CANADA
Starovasnik, Melissa A., San Francisco, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
Van Lookeren, Menno, San Francisco, CA, UNITED STATES
Vandlen, Richard, Hillsborough, CA, UNITED STATES
Watanabe, Colin K., Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Yansura, Daniel G., Pacifica, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002182673	A1	20021205
APPLICATION INFO.:	US 2001-157	A1	20011030 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-931836, filed on 16 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-929404, filed on 13 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-918585, filed on 30 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-908827, filed on 18 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-874503, filed on 5 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-854280, filed on 10 May 2001, PENDING

Continuation-in-part of Ser. No. US 2001-854208, filed on 10 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-816744, filed on 22 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-747259, filed on 20 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-644848, filed on 22 Aug 2000, PENDING Continuation-in-part of Ser. No. US 1999-380142, filed on 25 Aug 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-380138, filed on 25 Aug 1999, PENDING Continuation-in-part of Ser. No. US 1999-311832, filed on 14 May 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US21735	20010709
	WO 2001-US21066	20010629
	WO 2001-US19692	20010620
	WO 2001-US17800	20010601
	WO 2001-US6520	20010228
	WO 2000-US34956	20001220
	WO 2000-US32678	20001201
	WO 2000-US30873	20001110
	WO 2000-US23328	20000824
	WO 2000-US15264	20000602
	WO 2000-US7532	20000321
	WO 2000-US5841	20000302
	WO 2000-US5601	20000301
	WO 2000-US4341	20000218
	WO 1999-US31274	19991230
	WO 1999-US10733	19990514
	WO 1999-US5028	19990308
	US 2000-253646P	20001128 (60)
	US 2000-244072P	20001026 (60)
	US 2000-242837P	20001024 (60)
	US 2000-213807P	20000622 (60)
	US 2000-191007P	20000321 (60)
	US 2000-175481P	20000111 (60)
	US 1999-172096P	19991223 (60)
	US 1999-138387P	19990609 (60)
	US 1999-134287P	19990514 (60)
	US 1999-131022P	19990426 (60)
	US 1999-130232P	19990421 (60)
	US 1998-113621P	19981223 (60)
	US 1998-85579P	19980515 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 70 Drawing Page(s)
LINE COUNT: 8889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 11 USPATFULL

ACCESSION NUMBER: 2002:314711 USPATFULL

TITLE: IL-17 homologous polypeptides and therapeutic uses thereof

INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Fong, Sherman, Alameda, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., Burlingame, CA, UNITED STATES
Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES
Gurney, Austin, Belmont, CA, UNITED STATES
Li, Hanzhong, San Mateo, CA, UNITED STATES
Hillan, Kenneth, San Francisco, CA, UNITED STATES
Hymowitz, Sarah G., San Francisco, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
Starvovasnik, Melissa A., San Francisco, CA, UNITED STATES
Lookeren, Menno Van, San Francisco, CA, UNITED STATES
Vandlen, Richard, Hillsborough, CA, UNITED STATES
Watanabe, Colin, Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Yansura, Daniel G., Pacifica, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002177188	A1	20021128	
APPLICATION INFO.:	US 2001-874503	A1	20010605	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	WO 2001-US6520	20010228	
	WO 2000-US34956	20001220	
	WO 2000-US32678	20001201	
	WO 2000-US30873	20001110	
	WO 2000-US23328	20000824	
	WO 2000-US15264	20000602	
	WO 2000-US7532	20000321	
	WO 2000-US5841	20000302	
	WO 2000-US5601	20000301	
	WO 2000-US4341	20000218	
	WO 1999-US31274	19991230	
	WO 1999-US10733	19990514	
	WO 1999-US5028	19990308	
	US 2000-253646P	20001128	(60)
	US 2000-244072P	20001026	(60)
	US 2000-242837P	20001024	(60)
	US 2000-213807P	20000622	(60)
	US 2000-191007P	20000321	(60)
	US 2000-175481P	20000111	(60)
	US 1999-172096P	19991223	(60)
	US 1999-138387P	19990609	(60)
	US 1999-134287P	19990514	(60)
	US 1999-131022P	19990426	(60)
	US 1999-130232P	19990421	(60)
	US 1998-113621P	19981223	(60)
	US 1998-85579P	19980515	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

NUMBER OF CLAIMS: 60

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 54 Drawing Page(s)
LINE COUNT: 8549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 11 USPATFULL
ACCESSION NUMBER: 2001:202586 USPATFULL
TITLE: Methods for treating an ischemic disorder and improving stroke outcome
INVENTOR(S): Pinsky, David J., Riverdale, NY, United States
Stern, David, Great Neck, NY, United States
Schmidt, Ann Marie, Franklin Lakes, NJ, United States
Rose, Eric A., Tenafly, NJ, United States
Connolly, E. Sander, New York, NY, United States
Solomon, Robert A., Palisades, NY, United States
Prestigiacomo, Charles J., Teaneck, NJ, United States
PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6316403	B1	20011113	
	WO 9813058		19980402	
APPLICATION INFO.:	US 1999-269426		19990625	(9)
	WO 1997-US17229		19970925	
			19990625	PCT 371 date
			19990625	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-721447, filed on 27 Sep 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Peselev, Elli
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 103 Drawing Figure(s); 60 Drawing Page(s)
LINE COUNT: 5590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides for a method of treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 11 USPATFULL
ACCESSION NUMBER: 1998:150697 USPATFULL
TITLE: Differential separation assay methods and test kits
INVENTOR(S): Manian, Bala S., Los Altos Hills, CA, United States
Ghazarossian, Vartan E., Menlo Park, CA, United States
Hayter, Paul G., Los Altos, CA, United States
PATENT ASSIGNEE(S): Biometric Imaging, Inc., Mountain View, CA, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843680		19981201
APPLICATION INFO.:	US 1995-425718		19950419 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-277161, filed on 19 Jul 1994, now abandoned which is a continuation of Ser. No. US 1992-927928, filed on 10 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-828407, filed on 31 Jan 1992, now patented, Pat. No. US 5137609

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chin, Christopher L.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analytes can be detected from among closely related substances by reacting the analyte in a test sample with a labeled binding agent which specifically binds to the analyte to form a complex. The labeled binding agent is supplied in excess, and the complex is identified through a time window relative to the detection of the excess unbound agent. The complex and labeled binding agent are isolated on a separation media and identified by the differential rate of migration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>